Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982968172> ?p ?o ?g. }
- W2982968172 endingPage "2148" @default.
- W2982968172 startingPage "2148" @default.
- W2982968172 abstract "Background: Over 300 somatic molecular variants in hematologic diseases are either specified as diagnostic criteria in the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues, recognized as potentially actionable biomarkers in the National Comprehensive Cancer Network (NCCN) compendia, or supported by published well-powered clinical studies. Moreover, new molecular alterations with potential clinical implications in hematologic disease are continuously emerging in the scientific literature. These have critical use for a wide spectrum of clinicians, including hematopathologists who diagnose patient-specific hematologic malignancies, heme-oncologists who direct patient care, and clinical trial nurses who assist patients in finding appropriate clinical trials. Importantly, the utility of this information critically depends on the clinician's ability to interpret the significance of variants in a point-of-care setting. Therefore, there is an urgent and unmet need for a clinical decision support system that 1) distills the clinical implications associated with molecular alterations into a standardized and easily interpretable format and 2) democratizes access of this information to all members of the heme-oncology community. Methods: OncoKB is an established expert-guided precision oncology knowledge base that annotates the oncogenic effect and therapeutic implications of somatic molecular alterations (Chakravarty, D. et al., JCOPO, 2017). Previously, OncoKB was focused primarily on solid tumor mutation annotation. Recently, we expanded OncoKB to include alterations in hematologic malignancies. The heme-specific annotation efforts were guided by heme-oncology and hematopathology physician scientists at Memorial Sloan Kettering (MSK). Supplementing the previously published therapeutic levels of evidence (Fig. 1a), we further added level of evidence systems for diagnostic and prognostic implications (Fig. 1b, c). These three sets of evidence levels are consistent with the criteria set forth by the joint consensus of the ASCO/CAP/AMP guidelines (Li, MM. et al., J Mol Diagn, 2017). We assigned the newly curated heme-specific molecular alterations with diagnostic, prognostic or therapeutic levels of evidence, when applicable. Finally, we annotated and analyzed 1569 hematologic tumor samples from the AACR Project GENIE (release 6.1) with these levels of evidence. Results: In addition to alterations with both solid and heme clinical implications already curated in OncoKB, we annotated 288 unique heme-specific mutations, fusions, and copy number alterations in 156 newly curated cancer-associated genes. Based on MSK-expert consensus, the WHO and NCCN guidelines, and the scientific literature, we identified a total of 192 alterations with unique diagnostic levels of evidence, 65 alterations with unique prognostic levels of evidence and 55 alterations with unique therapeutic levels of evidence across 13 major hematologic tumor types (Fig. 2). To test the utility of OncoKB, we annotated all genomic events in 1569 heme cancer samples in 89 hematologic malignancies in the AACR GENIE cohort (V6.1) (Fig. 3a). Thirty-eight percent of samples harbored at least one potentially actionable alteration, and 8% were predictive of clinical benefit from an FDA-approved drug (Fig. 3b). Conclusions: OncoKB heme data is publicly available both through the web resource http://oncokb.org and through incorporation into the cBioPortal for Cancer Genomics. Heme-specific molecular alterations are used to make an accurate diagnosis, inform prognosis, optimize the use of stem cell transplant, and to link patients with the optimal mechanism-based therapies in the clinical trial setting and in routine clinical practice. This is the first study to annotate and analyze actionability of heme samples. In this proof-of-principle study, we demonstrate the ability to annotate clinical samples with their diagnostic, prognostic and therapeutic implications in a point-of-care setting. Disclosures Roshal: Celgene: Other: Provision of Services; Auron Therapeutics: Equity Ownership, Other: Provision of services; Physicians' Education Resource: Other: Provision of services. Ho:Invivoscribe, Inc.: Honoraria. Knorr:Fate Therapeutics: Patents & Royalties. LaFave:Epizyme: Patents & Royalties. Arcila:Invivoscribe, Inc.: Consultancy, Honoraria. Berger:Roche: Consultancy. Solit:Pfizer: Consultancy; Lilly Oncology: Honoraria; Vivideon Therapeutics: Consultancy; Loxo Oncology: Consultancy, Equity Ownership; Illumina: Consultancy. Dogan:Celgene: Consultancy; Seattle Genetics: Consultancy; Corvus Pharmaceuticals: Consultancy; Roche: Consultancy, Research Funding; Novartis: Consultancy; Takeda: Consultancy. Levine:C4 Therapeutics: Membership on an entity's Board of Directors or advisory committees; Qiagen: Membership on an entity's Board of Directors or advisory committees; Isoplexis: Membership on an entity's Board of Directors or advisory committees; Loxo: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Gilead: Consultancy; Imago Biosciences: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Lilly: Honoraria; Prelude Therapeutics: Research Funding; Roche: Consultancy, Research Funding." @default.
- W2982968172 created "2019-11-22" @default.
- W2982968172 creator A5000774517 @default.
- W2982968172 creator A5000845600 @default.
- W2982968172 creator A5001208934 @default.
- W2982968172 creator A5008245068 @default.
- W2982968172 creator A5013778834 @default.
- W2982968172 creator A5014978419 @default.
- W2982968172 creator A5019380256 @default.
- W2982968172 creator A5024505450 @default.
- W2982968172 creator A5025660159 @default.
- W2982968172 creator A5029793636 @default.
- W2982968172 creator A5033125884 @default.
- W2982968172 creator A5035392910 @default.
- W2982968172 creator A5037092952 @default.
- W2982968172 creator A5039241152 @default.
- W2982968172 creator A5041816884 @default.
- W2982968172 creator A5053263729 @default.
- W2982968172 creator A5055506298 @default.
- W2982968172 creator A5065116165 @default.
- W2982968172 creator A5079953387 @default.
- W2982968172 creator A5081913602 @default.
- W2982968172 creator A5082475426 @default.
- W2982968172 creator A5087361329 @default.
- W2982968172 creator A5087788162 @default.
- W2982968172 date "2019-11-13" @default.
- W2982968172 modified "2023-09-30" @default.
- W2982968172 title "Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase" @default.
- W2982968172 doi "https://doi.org/10.1182/blood-2019-125068" @default.
- W2982968172 hasPublicationYear "2019" @default.
- W2982968172 type Work @default.
- W2982968172 sameAs 2982968172 @default.
- W2982968172 citedByCount "2" @default.
- W2982968172 countsByYear W29829681722022 @default.
- W2982968172 crossrefType "journal-article" @default.
- W2982968172 hasAuthorship W2982968172A5000774517 @default.
- W2982968172 hasAuthorship W2982968172A5000845600 @default.
- W2982968172 hasAuthorship W2982968172A5001208934 @default.
- W2982968172 hasAuthorship W2982968172A5008245068 @default.
- W2982968172 hasAuthorship W2982968172A5013778834 @default.
- W2982968172 hasAuthorship W2982968172A5014978419 @default.
- W2982968172 hasAuthorship W2982968172A5019380256 @default.
- W2982968172 hasAuthorship W2982968172A5024505450 @default.
- W2982968172 hasAuthorship W2982968172A5025660159 @default.
- W2982968172 hasAuthorship W2982968172A5029793636 @default.
- W2982968172 hasAuthorship W2982968172A5033125884 @default.
- W2982968172 hasAuthorship W2982968172A5035392910 @default.
- W2982968172 hasAuthorship W2982968172A5037092952 @default.
- W2982968172 hasAuthorship W2982968172A5039241152 @default.
- W2982968172 hasAuthorship W2982968172A5041816884 @default.
- W2982968172 hasAuthorship W2982968172A5053263729 @default.
- W2982968172 hasAuthorship W2982968172A5055506298 @default.
- W2982968172 hasAuthorship W2982968172A5065116165 @default.
- W2982968172 hasAuthorship W2982968172A5079953387 @default.
- W2982968172 hasAuthorship W2982968172A5081913602 @default.
- W2982968172 hasAuthorship W2982968172A5082475426 @default.
- W2982968172 hasAuthorship W2982968172A5087361329 @default.
- W2982968172 hasAuthorship W2982968172A5087788162 @default.
- W2982968172 hasBestOaLocation W29829681721 @default.
- W2982968172 hasConcept C104317684 @default.
- W2982968172 hasConcept C121608353 @default.
- W2982968172 hasConcept C126322002 @default.
- W2982968172 hasConcept C142724271 @default.
- W2982968172 hasConcept C143998085 @default.
- W2982968172 hasConcept C163763905 @default.
- W2982968172 hasConcept C174475383 @default.
- W2982968172 hasConcept C179786068 @default.
- W2982968172 hasConcept C2779060813 @default.
- W2982968172 hasConcept C2779134260 @default.
- W2982968172 hasConcept C30481170 @default.
- W2982968172 hasConcept C54355233 @default.
- W2982968172 hasConcept C60644358 @default.
- W2982968172 hasConcept C71924100 @default.
- W2982968172 hasConcept C86803240 @default.
- W2982968172 hasConceptScore W2982968172C104317684 @default.
- W2982968172 hasConceptScore W2982968172C121608353 @default.
- W2982968172 hasConceptScore W2982968172C126322002 @default.
- W2982968172 hasConceptScore W2982968172C142724271 @default.
- W2982968172 hasConceptScore W2982968172C143998085 @default.
- W2982968172 hasConceptScore W2982968172C163763905 @default.
- W2982968172 hasConceptScore W2982968172C174475383 @default.
- W2982968172 hasConceptScore W2982968172C179786068 @default.
- W2982968172 hasConceptScore W2982968172C2779060813 @default.
- W2982968172 hasConceptScore W2982968172C2779134260 @default.
- W2982968172 hasConceptScore W2982968172C30481170 @default.
- W2982968172 hasConceptScore W2982968172C54355233 @default.
- W2982968172 hasConceptScore W2982968172C60644358 @default.
- W2982968172 hasConceptScore W2982968172C71924100 @default.
- W2982968172 hasConceptScore W2982968172C86803240 @default.
- W2982968172 hasIssue "Supplement_1" @default.
- W2982968172 hasLocation W29829681721 @default.
- W2982968172 hasOpenAccess W2982968172 @default.
- W2982968172 hasPrimaryLocation W29829681721 @default.
- W2982968172 hasRelatedWork W2066931960 @default.
- W2982968172 hasRelatedWork W2085367843 @default.
- W2982968172 hasRelatedWork W2118075882 @default.
- W2982968172 hasRelatedWork W2333838168 @default.
- W2982968172 hasRelatedWork W2465781320 @default.